Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal
Nuvalent's shares surged 39% to $123 after GlaxoSmithKline agreed to acquire the cancer drug developer for $10.6 billion, enhancing its oncology portfolio.
CNBC
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion. The acquisition could help GSK offset a drop in revenue expected ...
Morningstar
UPDATE: GSK buys cancer drug developer Nuvalent for USD10.6 billion
(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday.
Nuvalent to Be Acquired by GSK in Cash Deal
Nuvalent ( (NUVL)) has shared an update. On 9 June 2026, Nuvalent entered into a merger agreement under which GlaxoSmithKline will launch a tender offer to acquire all Nuvalent Class A and B shares ...
GEN
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments
Two GlaxoSmithKline (GSK) R&D team members at work in the company’s Upper Merion, PA, laboratory. GSK has agreed to acquire Nuvalent for $10.6 billion, in a deal designed to strengthen the buyer’s ...
U.S. News & World Report
GSK Boosts Cancer Portfolio With $10.6 Billion Nuvalent Takeover
GSK Boosts Cancer Portfolio With $10.6 Billion Nuvalent Takeover By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer ⁠drug ⁠developer Nuvalent for ...
The Business Journals
GSK to pay $10.6B for Cambridge cancer biotech
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would give GSK two late ...